SEC Form 4 · accession 0001520138-26-000346
BioNexus Gene Lab Corp · BGLC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Set Fui Chong
Officer — Chief Financial Officer
Period of report
Aug 13, 2026
Accepted (ET)
Aug 14, 2026 · 5:17 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001737523
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1 | Aug 13, 2026 | A | 96,774 | — | A | 96,774 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a fully vested Other Stock-Based Award of 96,774 shares of common stock, no par value, granted on August 13, 2026 under the BioNexus Gene Lab Corp. 2025 Equity Incentive Plan. The award was granted for completed services, for no cash consideration and valued for Plan purposes at $1.55 per share (the Nasdaq closing price on August 12, 2026).